Blog Listing

March 17 Newsletter

EVIDENCE BASED TRADING – Dr. James C Krider

March 17, 2017, momentum stock universe.

3-17-17 Dr Krider 30 day performance

3-17-17 Dr krider ytd performance

Dr. Krider’s managed portfolio YTD performance is 10.65% compared to the S&P 500 6.72%. This includes option trades. Dr. Krider’s 30-day trailing performance, including option trades, relative to the S&P 500 is 4.46% to 1.33%.

The dip from February dip has been completely erased and the managed portfolio is doing quite nicely. As explained in previously newsletters, the temporary underperformance represented the downgrade of NVIDIA and we weathered the storm. We added to the position by selling puts and further made money selling covered calls. The NVIDIA stock was called on Friday from the covered call leaving our performance well above the S&P 500. Also, the March portfolio once more reflects a pure momentum selection and is outperforming the S&P 500 2:1. Not bad.

Dr. James Krider creates a new stock portfolio monthly consisting of quality momentum stocks. Most portfolios contain 20 stocks and are active for three months. The portfolio is managed per the guidelines provided in the educational section   To view the currently active portfolios, go to Dr. Krider’s momentum stock universe. It is completely free and updated weekly.

To follow the actual and pending trades, subscribe to our premium service.

Dr. Krider’s managed portfolio includes option trades.

Disclosure: I am long in AAPL, ABX, AMAT, ANTM, ARCC, AVGO, BAC, BX, CI, CIEN, DD, DIS, DOW, FB, GLW, HCA, JPM, LRCX, MBT, MO, OLN, ORN, PWR, S, SPY, ST, STX, TMUS, TWTR, TXN, V, WB, WDC, and X.  I hold option positions in ACAD, AMAT, COH,MU, NVDA, STMP, TWTR, and WB.

MARKET REVIEW        

Three-month chart: We still have a major support level at $228 and minor support at $236. RSquared remains tight at 0.88 and the regression channel is increasing with the SPY near the bottom of the channel. The moving average slope is drifting down and is currently 23 degrees. Minor support is being tested once more.

3-17-17 three month

One-month chart: shows a continued weakening at RSquared and insignificant at 0.224. The MA20 slope is also continuing down and is currently 25 degrees. The MA20 was broken on Friday, 3/17.

3-17-17 one month

Technical analysis is neutral for the short-term (30-days) and remains bullish for intermediate- and long-term timeframes.

Overall: The market remains bullish long term. However, we appear to be consolidating and moving sideways. We broke the MA20 and will look to Monday for confirmation or rejection. We are also at the bottom of 30-day regression channel and testing minor support.

NEXT WEEKS PLAN

I am currently 60% invested in stock. This represents momentum stocks and stocks assigned to me from option trades. Currently I have 10 stocks outside of the momentum group. I will be cautious on Monday to determine which way the market wants to move. I will be placing some covered calls only if the market is down.

The premium service has all my option and momentum trades that you can follow in real time.

To view the complete list of current momentum stocks, go to the momentum universe page. This is a free service.

Happy trading,

Dr. James Krider MD

 

 

 

 

 

James Krider, MD

Dr. James C Krider is a practicing family physician in Apple Valley, CA. Dr. Krider is a licensed insurance agent in the states of California (0I65488) and Nevada specializing in Medicare Advantage and Life insurance, an important aspect of wealth planning.

Dr. James C Krider is an Investment Advisor Representative licensed in the state of Nevada and is President of Krider Wealth Management, an Investment Advisory corporation in Nevada.

These comments were prepared by James Krider, MD, an investment advisor representative of Krider Wealth Management, LLC, a Nevada state registered investment advisor. The information herein was obtained from various sources believed to be reliable; however, we do not guarantee its accuracy or completeness. The information in this report is given as of the date indicated. We assume no obligation to update this information, or advise on further developments relating to securities discussed in this report. Opinions expressed are subject to change without notice. Opinions of individual representatives may not be those of the Firm. Additional information is available upon request. The information contained in this document is prepared for general circulation and is circulated for general information only. It does not address specific investment objectives, or the financial situation and the particular needs of any recipient. Investors should not attempt to make investment decisions solely based on the information contained in this communication as it does not offer enough information to make such decisions and may not be suitable for your personal financial circumstances. You should consult with your financial professional prior to making such decisions. PAST PERFORMANCE SHOULD NOT BE CONSIDERED INDICATIVE OF FUTURE PERFORMANCE. ANY INVESTMENT CONTAINS RISK INCLUDING THE RISK OF TOTAL LOSS. This document does not constitute an offer, or an invitation to make an offer, to buy or sell any securities discussed herein.


Leave a Reply